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b-Lactamases comprise the major defence of
Gram-negative bacteria against b-lactam antibio-
tics. These enzymes have evolved over decades of
b-lactam use and have developed the capability of
targeting a growing number of antimicrobial com-
pounds. The incidence of infection with these
drug-resistant pathogens has continued to increase
on a global scale. Nosocomial infections due to
extended-spectrum b-lactamase (ESBL)-produ-
cing organisms have become a growing cause of
morbidity and mortality. Screening methodology
has been developed to identify these pathogens in
most microbiology laboratory settings.
This timely supplement describes the current
scene by reviewing the emergence and implica-
tions of metallo-b-lactamases (MBLs) in Gram-
negative bacteria, addressing pharmacokinetics
and pharmacodynamics in treating infections
caused by ESBL-producing organisms. The sup-
plement represents the proceedings of a sympo-
sium that was held at the 15th ECCMID
in Copenhagen, Denmark, where the speakers
were Dr D. Andes, University of Wisconsin,
Madison, WI, USA, Dr T. R. Walsh, University
of Bristol, UK and Prof G. A. Richards, University
of Witwatersrand, South Africa.
Dr Walsh reviewed resistance in Enterobacte-
riaceae and non-fermenters, such as Acinetobacter
and Pseudomonas aeruginosa, and showed that
quinolone and broad-spectrum b-lactam resistance
is increasing in these organisms. He also explored
their mechanisms of resistance. Of the intrinsic
mechanisms of resistance, he reviewed the many
different efﬂux pumps present in Gram-negative
bacilli. Of the acquired resistance mechanisms, he
discussed the MBLs and argued that these MBLs
represent the largest threat for two reasons: the
genes coding for these enzymes are often found on
cassettes, and there is no treatment. He concluded
that resistance will get worse, not better, and that,
based on the largest market, new drugs are largely
directed towards Gram-positive bacteria causing
respiratory tract infections. Findings such as these
give fresh impetus to the campaign to develop new
antimicrobial compounds. However, Dr Walsh
concluded that there are no new anti-Gram-nega-
tive drugs expected for the next 6–8 years.
Dr Andes discussed what matters for the treat-
ment of infections caused by ESBL-producing
strains. He showed that poor outcome has not only
been reported when patients infected with ESBL-
producing organisms are treated with antimicro-
bial agents to which the organism is resistant, but
also that poor outcome can occur in patients with
organisms categorised as intermediate or suscep-
tible. To address this situation, he examined the
relationshipsbetweenantibioticdrugexposure, the
in-vitro potency of the antibiotic, and outcome.
Animal experiments showed that the pharmacoki-
netic ⁄pharmacodyamic target of a %T > MIC of
40–50% was similar among the various strains.
Examination of this target relative to the distribu-
tion of MICs for organisms from surveillance
studies and human pharmacokinetic studies
showed why reports demonstrate treatment fail-
ures with so-called ‘susceptible’ pathogens.
He discussed the tools that are now being used to
re-examine these susceptibility breakpoints,
including consideration of MIC distribution, the
pharmacokinetic ⁄pharmacodyamic target, human
pharmacokinetic estimates and emerging clinical
data. He concluded that the current in-vitro suscep-
tibility level appears tobedeﬁnedat a concentration
likely to be associated with treatment failure.
Professor Richards addressed the clinical
challenges of treating severe sepsis. He under-
scored that management of the critically ill patient
requires more than appropriate antibiotic therapy.
He reviewed studies concerning the association
between inappropriate therapy and mortality and
concluded that all of these studies clearly show that
antibiotic therapy should be early and adequate.
As a consequence, empirical antibiotic therapy
should be based on local surveillance resistance
data. Professor Richards addressed some very
controversial topics, such as monotherapy vs.
combination therapy, de-escalation, rotation and
cycling, and duration of therapy. He also reviewed
ways of reducing the incidence of hospital-
acquired infections, which would result in a
reduction in antibiotic pressure and, hence, the
emergence of antibiotic resistance.
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